Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · RELMADA THERAPEUTICS, INC. (RLMD)

Relmada Therapeutics appoints Bipin Dalmia as Chief Business Officer

Neutral Impact 3 of 5 leadership Written later

Relmada Therapeutics announced on July 28, 2026 that it appointed Bipin Dalmia, PhD, MBA, as Chief Business Officer, reporting to CEO Sergio Traversa. He will lead corporate strategy, commercial planning, and business development as the company advances NDV-01 toward late-stage development. The filing does not disclose compensation terms or financial figures for the appointment.

Key points

  • Appointment announced July 28, 2026; Dalmia reports directly to CEO Sergio Traversa
  • Responsibilities include corporate strategy, commercial planning, and business development
  • Previously Senior Vice President, Global Head of Portfolio Strategy & Business Development at Ferring Pharmaceuticals, with a 14-year tenure there
  • The filing does not disclose compensation or other financial terms of the appointment

The filing

CompanyRELMADA THERAPEUTICS, INC. (RLMD)
Form8-K, current report
Filed with the SECJul 28, 2026, 8:35 AM ET
Accession number0001213900-26-082007

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.